Six Swiss drugs feature in the top 50 best-sellers

Top 50 global drugs in 2025, based on total revenue and year-on-year growth rate.

Novartis: Entresto, Cosentyx, Kisqali, Kesimpta
Roche: Ocrevus, Vabysmo